ROSEN, SKILLED INVESTOR COUNSEL, Encourages enCore Energy Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EU

(NASDAQ:EU), NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of enCore Energy Corp. (NASDAQ: EU) between March 28, 2024 and March 2, 2025, both dates inclusive (the “Class Period”), of the important May 13, 2025 lead plaintiff deadline. SO WHAT: If […]

ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight

ROCKLATAN/ROCLANDA holds significant market potential for treating open-angle glaucoma (OAG) and ocular hypertension by effectively reducing IOP. This fixed-dose combination merges the benefits of a Rho kinase inhibitor and a prostaglandin F2a analog, providing superior efficacy compared to monotherapies. DelveInsight's “ROCKLATAN/ROCLANDA Market Size, Forecast, and Market Insight Report” highlights the details around ROCKLATAN/ROCLANDA, which is

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple preclinical programs have been accepted

Rogers Communications 1Q25 Investment Community Teleconference April 23, 2025 at 8:00 a.m. ET

(TSX:RCI-A),(TSX:RCI-B),(NYSE:RCI), TORONTO, March 25, 2025 (GLOBE NEWSWIRE) — Rogers Communications Inc. (TSX: RCI.A and RCI.B) (NYSE: RCI) plans to release its first quarter 2025 financial results on Wednesday, April 23, 2025, before North American financial markets open. The results will be distributed by newswire and posted at investors.rogers.com. Rogers' management will host its quarterly teleconference

EPSIUM ENTERPRISE LIMITED Announces Pricing of US$5.0 Million Initial Public Offering

EPSIUM ENTERPRISE LIMITED (the “Company” or “EPSIUM”), a company engaged in importing and wholesaling primarily alcoholic beverages in Macau,today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital

Purelight Power Expands to Minneapolis, Making Solar Energy More Affordable for Homeowners

Purelight Power, a top provider of residential solar solutions, is excited to announce its expansion into Minneapolis. With a commitment to innovation and a customer-first approach, the company brings cutting-edge solar technology to homeowners across the Twin Cities. The goal? To make clean, renewable energy more accessible and help Minnesotans save on electricity costs. https://mma.prnewswire.com/media/2591611/Purelight_Power__logo.jpg

HII’s Ingalls Shipbuilding Launches Guided Missile Destroyer Future USS Jeremiah Denton (DDG 129)

(NYSE:HII), PASCAGOULA, Miss., March 25, 2025 (GLOBE NEWSWIRE) — HII's (NYSE: HII) Ingalls Shipbuilding division successfully launched future USS Jeremiah Denton (DDG 129) today, the third Flight III Arleigh Burke-class destroyer to be built at the shipyard. Shipbuilders transferred DDG 129 from land to the company's dry dock using translation railcars to support the ship

ATKR Investors Have Opportunity to Lead Atkore Inc. Securities Fraud Lawsuit

https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock ofAtkore Inc. (NYSE: ATKR) between February 1, 2024 and February 3, 2025, both dates inclusive (the “Class Period”), of the important April 23, 2025 lead plaintiff deadline. So what: If you purchased Atkorecommon stock during the Class Period you

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced upcoming poster presentations further characterizing the preclinical profiles of its novel ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib, at the American Association for Cancer Research (AACR) Annual Meeting 2025 from April 25-30, 2025,

FMC Purchasers Have Opportunity to Lead FMC Corporation Securities Fraud Lawsuit

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FMC Corporation (NYSE: FMC) between November 16, 2023 and February 4, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg So what: If you purchased FMC securities during the Class Period you may

Scroll to Top